Halozyme Therapeutics HALO Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | $444.09M+57.7% | $281.59M+39.3% | $202.13M-49.8% | ||
| $11.39M+10.6% | $10.3M-6.8% | $11.05M+71.6% | $6.44M+114% | ||
| $51.57M+18.9% | $43.39M+18.5% | $36.62M+50.1% | $24.4M+17.2% | ||
| —— | —— | -$34.51M+13.7% | -$40.01M-126% | ||
| $48.7M— | $0— | $0— | —— | ||
| $128.06M+72.5% | $74.25M+2,124% | $3.34M-96.0% | $83.94M+1,343% | ||
| -$2.55M-104% | $69.36M— | —— | $17.48M+334% | ||
| $6.21M-86.8% | $46.99M— | —— | —— | ||
| —— | -$5.36M— | —— | —— | ||
| $76.66M+7.9% | $71.05M-3.7% | $73.77M+71.0% | $43.15M— | ||
| $7.51M+2.1% | $7.35M+0.6% | $7.3M-6.8% | $7.84M+115% | ||
| $651.56M+36.0% | $479.06M+23.3% | $388.57M+61.8% | $240.11M-19.8% | ||
| $6.97M-34.8% | $10.7M— | —— | $4.81M+230% | ||
| $247.36M-61.8% | $647.6M+121% | $292.91M+14.8% | $255.21M-60.9% | ||
| $722.25M+82.6% | $395.57M+87.2% | $211.3M-71.7% | $746.13M+201% | ||
| $284.89M— | $0— | $0— | —— | ||
| —— | —— | —— | -$487.01M-19.9% | ||
| —— | —— | —— | —— | ||
| —— | -$218.86M— | —— | $374.77M— | ||
| —— | -$2.52M— | —— | $115.48M+498% | ||
| $11.43M+8.2% | $10.57M-7.4% | $11.41M+86.8% | $6.11M+85.3% | ||
| $134.64M+67.0% | $80.62M+154% | $31.76M+95.7% | $16.22M+4,226% | ||
| $3.3M-69.8% | $10.92M+72.8% | $6.32M+671% | -$1.11M+51.0% | ||
| $7.51M+2.1% | $7.35M+0.6% | $7.3M-6.8% | $7.84M+115% | ||
| $76.66M+7.9% | $71.05M-3.7% | $73.77M+71.0% | $43.15M— | ||
| -$951K+10.9% | -$1.07M+16.0% | -$1.27M-241% | $903K+20.2% | ||
| —— | —— | -$34.51M+13.7% | -$40.01M-126% | ||
| —— | -$5.36M— | —— | —— | ||
| $284.89M— | $0— | $0— | —— | ||
| $287.77M— | $0— | $0— | —— | ||
| —— | —— | —— | —— | ||
| $722.25M+82.6% | $395.57M+87.2% | $211.3M-71.7% | $746.13M+201% | ||
| —— | —— | —— | $746.13M+201% | ||
| $5.48M— | $0— | $0— | —— | ||
| —— | $3.08M+19.7% | $2.57M-92.5% | $34.44M— | ||
| $134.64M+67.0% | $80.62M+154% | $31.76M+95.7% | $16.22M+4,426% | ||
| $644.59M+37.6% | $468.37M+25.5% | $373.28M+58.6% | $235.3M-21.0% | ||
| $644.59M+37.6% | $468.37M+25.5% | $373.28M+58.6% | $235.3M-21.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Halozyme Therapeutics generate?
- Halozyme Therapeutics (HALO) generated $677.4M in operating cash flow over the trailing twelve months.
- What is Halozyme Therapeutics's free cash flow?
- After $9.8M of capital expenditures, Halozyme Therapeutics's free cash flow was $667.7M over the trailing twelve months, up 34.7% year over year.
- Where does Halozyme Therapeutics's cash flow data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
